A meta-analysis of 27 randomized clinical trials [13] found no association between GLP-1 RAs and suicidal ideation or suicide
Ninety-five percent of GLP-1 users report eating smaller portions, and 87% are snacking less, and 81% are eating less frequentlysignaling a significant shift in eating habits among users
But that will depend heavily on whether approved medicines become genuinely affordable
Risk increases with: Too few calories or skipped meals , leading to protein breakdown for energy Inadequate protein intake , especially near minimal dietary requirements rather than weight-lossappropriate targets Lack of resistance training , removing the signal to maintain muscle Micronutrient deficiencies , such as low vitamin D, which can impair muscle function Preventing undernutrition dramatically reduces the risk of clinically meaningful muscle loss. How Common Is Lean-Mass Loss with GLP-1/GIP Therapy
2024 Dec 4;14(1)
Exenatide, a 39-amino acid peptide, is the first GLP-1R agonists approved by the US FDA in 2005 and EMA in 2007